Growth rate-corrected (GR) dose-response metrics across a panel of 71 breast cancer cell lines treated with a library of small molecule and antibody perturbagens. Dataset 1 of 4: Relative cell counts and normalized growth rate inhibition values across technical replicates. - Dataset (ID:20268)
Download: Excel (XLSX), Comma-separated (CSV)
| Cell | Clinical Subtype | Transcriptional Subtype | Small Molecule | Antibody | Perturbagen Target | Perturbagen Class | Perturbagen Concentration | Perturbagen Conc Unit | Biological Replicate ID | Relative Cell Count | Normalized Growth Rate Inhibition Value | Nominal Division Rate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| BT-483 | HR+ | Luminal | Nilotinib | ABL | nRTK | 0.00256 | uM | 10696.145 | 0.9318 | 0.6160 | 0.3316 | |
| BT-483 | HR+ | Luminal | Nilotinib | ABL | nRTK | 0.0128 | uM | 10696.145 | 0.9911 | 0.9468 | 0.3316 | |
| BT-483 | HR+ | Luminal | Nilotinib | ABL | nRTK | 0.064 | uM | 10696.145 | 0.9794 | 0.8783 | 0.3316 | |
| BT-483 | HR+ | Luminal | Nilotinib | ABL | nRTK | 0.32 | uM | 10696.145 | 0.9866 | 0.9200 | 0.3316 | |
| BT-483 | HR+ | Luminal | Nilotinib | ABL | nRTK | 1.6 | uM | 10696.145 | 0.9576 | 0.7553 | 0.3316 | |
| BT-483 | HR+ | Luminal | Nilotinib | ABL | nRTK | 8 | uM | 10696.145 | 0.8694 | 0.3114 | 0.3316 | |
| BT-483 | HR+ | Luminal | Nilotinib | ABL | nRTK | 40 | uM | 10696.145 | 0.9566 | 0.7498 | 0.3316 | |
| BT-483 | HR+ | Luminal | Nilotinib | ABL | nRTK | 200 | uM | 10696.145 | 0.9441 | 0.6817 | 0.3316 | |
| BT-483 | HR+ | Luminal | Nilotinib | ABL | nRTK | 0.000512 | uM | 11855.145 | 0.9450 | 0.7890 | 0.5070 | |
| BT-483 | HR+ | Luminal | Nilotinib | ABL | nRTK | 0.00256 | uM | 11855.145 | 0.9058 | 0.6454 | 0.5070 | |
| BT-483 | HR+ | Luminal | Nilotinib | ABL | nRTK | 0.0128 | uM | 11855.145 | 0.9493 | 0.8050 | 0.5070 | |
| BT-483 | HR+ | Luminal | Nilotinib | ABL | nRTK | 0.064 | uM | 11855.145 | 0.9314 | 0.7386 | 0.5070 | |
| BT-483 | HR+ | Luminal | Nilotinib | ABL | nRTK | 0.32 | uM | 11855.145 | 0.9768 | 0.9096 | 0.5070 | |
| BT-483 | HR+ | Luminal | Nilotinib | ABL | nRTK | 1.6 | uM | 11855.145 | 0.9552 | 0.8270 | 0.5070 | |
| BT-483 | HR+ | Luminal | Nilotinib | ABL | nRTK | 8 | uM | 11855.145 | 0.9007 | 0.6271 | 0.5070 | |
| BT-483 | HR+ | Luminal | Nilotinib | ABL | nRTK | 40 | uM | 11855.145 | 0.8522 | 0.4588 | 0.5070 | |
| BT-483 | HR+ | Luminal | Nilotinib | ABL | nRTK | 200 | uM | 11855.145 | 0.8176 | 0.3444 | 0.5070 | |
| BT-549 | TNBC | Basal B | Nilotinib | ABL | nRTK | 0.000512 | uM | 12305.17 | 0.9992 | 0.9994 | 2.7728 | |
| BT-549 | TNBC | Basal B | Nilotinib | ABL | nRTK | 0.00256 | uM | 12305.17 | 1.0312 | 1.0223 | 2.7728 | |
| BT-549 | TNBC | Basal B | Nilotinib | ABL | nRTK | 0.0128 | uM | 12305.17 | 0.9762 | 0.9827 | 2.7728 | |
| BT-549 | TNBC | Basal B | Nilotinib | ABL | nRTK | 0.064 | uM | 12305.17 | 0.9581 | 0.9694 | 2.7728 | |
| BT-549 | TNBC | Basal B | Nilotinib | ABL | nRTK | 0.32 | uM | 12305.17 | 0.9713 | 0.9791 | 2.7728 | |
| BT-549 | TNBC | Basal B | Nilotinib | ABL | nRTK | 1.6 | uM | 12305.17 | 0.9108 | 0.9337 | 2.7728 | |
| BT-549 | TNBC | Basal B | Nilotinib | ABL | nRTK | 8 | uM | 12305.17 | 0.6788 | 0.7392 | 2.7728 | |
| BT-549 | TNBC | Basal B | Nilotinib | ABL | nRTK | 40 | uM | 12305.17 | 0.7939 | 0.8403 | 2.7728 |